This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on Web of Science (13)  • Contact me when this article is cited  Related Content  • Similar articles in JAMA  Topic Collections  • Statistics and Research Methods  • Alert me on articles by topic  Social Bookmarking   What's this?

Gaps in Evidence From Interventional Trials

Jonathan Himmelfarb, MD

JAMA. 2007;297:2630-2633.

	Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

In recent years, chronic kidney disease has received increased attention as a leading public health problem.¹ The kidney disease burden, measured in terms of prevalence, associated economic costs, and morbidity, is substantial and increasing. In the United States, more than 400 000 individuals have end-stage renal disease (ESRD),² for which life can be sustained only with renal replacement therapy such as dialysis or kidney transplantation. In a recent population-based study of US residents 45 years and older, 9.5% had a first-degree relative with ESRD.³ It is estimated that by 2015, more than 700 000 individuals in the United States will have ESRD, and more than 107 000 ESRD-related deaths will occur annually.² Cardiovascular mortality in patients with ESRD is 10- to 20-fold higher than in the general population and is the leading cause of death.⁴ Mortality rates for patients with ESRD have shown only modest improvement over the past 2 . . . [Full Text of this Article]

Where Are the Interventional Trials?

Author Affiliation: Maine Medical Center, Portland.

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Organ Markets and the Ends of Medicine
Davis and Crowe
J Med Philos 2009;34:586-605.
ABSTRACT | FULL TEXT  

Effect of Dipyridamole plus Aspirin on Hemodialysis Graft Patency
Dixon et al.
NEJM 2009;360:2191-2201.
ABSTRACT | FULL TEXT  

Bilineal inheritance of type 1 autosomal dominant polycystic kidney disease (ADPKD) and recurrent fetal loss
Peces et al.
NDT Plus 2008;1:289-291.
ABSTRACT | FULL TEXT  

Commentary: Controversies in NICE guidance on chronic kidney disease
Landray and Haynes
BMJ 2008;337:a1793-a1793.
FULL TEXT  

Associations of Kidney Function with Cardiovascular Medication Use after Myocardial Infarction
Winkelmayer et al.
CJASN 2008;3:1415-1422.
ABSTRACT | FULL TEXT  

European best practice quo vadis? From European best practice guidelines (EBPG) to European renal best practice (ERBP)
Zoccali et al.
Nephrol Dial Transplant 2008;23:2162-2166.
FULL TEXT  

Impact of Activated Vitamin D and Race on Survival among Hemodialysis Patients
Wolf et al.
J. Am. Soc. Nephrol. 2008;19:1379-1388.
ABSTRACT | FULL TEXT  

The Third World Kidney Day: Looking Back and Thinking Forward
Shah et al.
CJASN 2008;3:309-311.
FULL TEXT  

World Kidney Day 2008: Think Globally, Speak Locally
Davis et al.
J. Am. Soc. Nephrol. 2008;19:413-416.
FULL TEXT  

The third World Kidney Day: looking back and thinking forward
Shah and Feehally
Nephrol Dial Transplant 2008;23:471-473.
FULL TEXT  

New results from the Modification of Diet in Renal Disease study: the importance of clinical outcomes in test strategies for early chronic kidney disease
Giles et al.
QJM 2008;101:155-158.
ABSTRACT | FULL TEXT  

Frequent Nocturnal Hemodialysis A Step Forward?
Kliger
JAMA 2007;298:1331-1333.
FULL TEXT